CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128.
| Image |  |
|---|---|
| Description | scientific article published on 25 May 2018 |
| Author/s |
author: Thomas D. Schmittgen |
| Publication date | May 25, 2018 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |